India-developed 'variant-proof' Covid vaccine likely in 2-3 years: Industry

Domestically produced variant-proof jabs are part of a global project to develop vaccines for future epidemics

India is emerging as a leading player in the world’s search for a “variant-proof” coronavirus vaccine that would work against all emerging variants of coronaviruses and future epidemics. If things go to plan, the pharma industry thinks an India-developed pan-coronavirus vaccine may be available in the next two to three years.

Out of the nine projects awarded by the Coalition for Epidemic Preparedness Innovations (CEPI), a partnership between public, private and philanthropic organisations to develop vaccines against future epidemics, two are from India. The Bharat Biotech, University of Sydney and ExcellGene consortium is the latest to be awarded $19.3 million by